Anti-TGFBR3 antibody produced in rabbit
SIGMA/HPA008257 - Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Synonym: Anti-βGlycan antibody produced in rabbit; Anti-TGF-β receptor type III precursor antibody produced in rabbit; Anti-TGFR-3 antibody produced in rabbit; Anti-Transforming growth factor-β receptor III antibody produced in rabbit
Product Type: Chemical
| antibody form | affinity isolated antibody |
| antibody product type | primary antibodies |
| application(s) | research pathology |
| biological source | rabbit |
| clone | polyclonal |
| conjugate | unconjugated |
| form | buffered aqueous glycerol solution |
| immunogen sequence | GYSGMDVTLLDPTCKAKMNGTHFVL |
| product line | Prestige Antibodies® Powered by Atlas Antibodies |
| Quality Level | 100 ![]() |
| shipped in | wet ice |
| species reactivity | human |
| storage temp. | −20°C |
| target post-translational modification | unmodified |
| technique(s) | immunohistochemistry: 1:50- 1:200 |
| UniProt accession no. | Q03167 ![]() |
| Application: | Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below. Immunohistochemistry (1 paper) ![]() |
| Biochem/physiol Actions: | Transforming growth factor β (TGF-β) interacts with TGF β receptor III (TGFBR3) which allows TGF-β to form a high affinity ternary comple with TGF-β receptor type II (TGFBRII). Thus, TGFBR3 plays an important role as a coreceptor to increase ligand binding to TGFBRII. It enhances TGF-β-mediated effects on the cells and eliminates the biological differences between TGF-β isoforms. TGFBR3 inhibits breast cancer cell invasion by shedding its ectodomain and producing soluble TGFBR3. Soluble TGFBR3 binds and sequesters TGF-β to decrease its signaling. |
| Disclaimer: | Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals. |
| Features and Benefits: | Prestige Antibodies® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section. Every Prestige Antibody is tested in the following ways: • IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues. • Protein array of 364 human recombinant protein fragments. |
| General description: | The gene TGFBR3 (Transforming growth factor β receptor III) is mapped to human chromosme 1p32-p33. |
| Immunogen: | TGF-β receptor type III precursor recombinant protein epitope signature tag (PrEST) |
| Legal Information: | Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany |
| Other Notes: | Corresponding Antigen APREST70460 |
| Physical form: | Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 1 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Storage Temp. | −20°C |
| UNSPSC | 12352203 |

